Cargando…
To Be or Not to Be: Surviving Immune‐Mediated Fetal Heart Disease
Autores principales: | Jaeggi, Edgar, Hornberger, Lisa, Cuneo, Bettina, Moon‐Grady, Anita J., Raboisson, Marie‐Josée, Lougheed, Jane, Diab, Karim, Mawad, Wadi, Silverman, Earl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333378/ https://www.ncbi.nlm.nih.gov/pubmed/35730606 http://dx.doi.org/10.1161/JAHA.122.026241 |
Ejemplares similares
-
Outcome of Antibody‐Mediated Fetal Heart Disease With Standardized Anti‐Inflammatory Transplacental Treatment
por: Mawad, Wadi, et al.
Publicado: (2022) -
Fetal Abdominal Obesity Detected at 24 to 28 Weeks of Gestation Persists until Delivery Despite Management of Gestational Diabetes Mellitus (Diabetes Metab J 2021;45:547-57)
por: Kim, Wonjin, et al.
Publicado: (2021) -
Development and Validation of a Fetal Cardiovascular Disease Severity Scale
por: Davey, Brooke T., et al.
Publicado: (2014) -
The ADHD debate: being mindful of complexity and wary of reductionist explanations and polarization Commentary on 'A social relational critique of the biomedical definition and treatment of ADHD; ethical, practical and political implications'
por: Thapar, Anita, et al.
Publicado: (2013) -
Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
por: Kong, Sung Hye, et al.
Publicado: (2017)